when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

LILLY · news · pharmadog

← back to LILLY

News mentioning LILLY

793 stories

Sep 29, 26STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four yearsstat

Sep 29, 26STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midtermsstat

Sep 29, 26Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengruifiercebiotech

Sep 28, 26‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futurefiercebiotech

Sep 28, 26STAT+: It really is bleak out there, and list prices matterstat

Sep 28, 26STAT+: AbbVie wins FDA nod for Parkinson’s pillstat

Sep 28, 26STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and morestat

Sep 28, 26Roche drops muscle-sparing obesity antibody after flunked interim analysisfiercebiotech

Sep 28, 26STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’stat

Sep 28, 266 immunology targets to sustain a mammoth I&I marketbiospace

Sep 25, 26STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemicstat

Sep 25, 26Jury awards Nektar $90M in suit against Lillyendpoints

Sep 25, 26This week in charts: Novo’s rise and fall and AI biotechs’ big haulbiopharma dive

Sep 25, 26STAT+: Lilly wins approval for once-weekly insulin shotstat

Sep 25, 26Nektar prevails in legal battle with Lilly over broken rezpeg partnershipbiospace

Sep 25, 26Endpoints 11 2026 winner NewLimit searches for a new class of anti-aging drugsendpoints

Sep 25, 26Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapyendpoints

Sep 25, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Sep 25, 26STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morestat

Sep 25, 26Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s databiopharma dive

Sep 25, 26Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectablesfiercebiotech

Sep 24, 26FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’biospace

Sep 24, 26FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novoendpoints

Sep 24, 26STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates saystat

Sep 24, 26Lilly’s latest China drug deal; Immunovant’s setback in lupusbiopharma dive

Sep 24, 26STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and morestat

Sep 24, 26Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalrybiospace

Sep 24, 26Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCarebiospace

Sep 24, 26In another China pact, Lilly makes a deal with InnoCare worth up to $3.35Bendpoints

Sep 24, 26STAT+: Momentum is building for a big change to how doctors get paidstat

← prevpage 7 of 27next →